fremtidbio.

OUR DEVELOPMENT PIPELINE

Discovery in motion.
Progress with purpose.

Two programmes advancing from discovery towards lead optimisation. Each next step builds on the work already completed.

AI · BIOINFORMATICS · EXPERIMENTAL SCIENCEProgramme update · November 2026
HOW TO READ THE PIPELINE
  • Completed
  • Next planned step
  • Future development

Small-molecule programme

Candidates selected

From target biology to selected compounds. Target identification, target validation, library screening and candidate selection are complete.

  1. Target identificationCompleted
  2. Target validationCompleted
  3. Library screeningCompleted
  4. Candidate selectionCompleted
  5. Lead optimisationNext
  6. Preclinical developmentFuture
  7. Clinical developmentFuture

NEXT MILESTONE / LEAD OPTIMISATION

Refine the selected candidates.

Lead optimisation is the next planned stage, building on the compounds selected through screening.

Discuss this programme

AMR peptide programme

Leads selected

Advancing peptides against antimicrobial resistance. Peptide design and screening are complete, and leads have been selected for further development.

  1. Peptide designCompleted
  2. ScreeningCompleted
  3. Lead selectionCompleted
  4. Lead optimisationNext
  5. Preclinical developmentFuture
  6. Clinical developmentFuture

NEXT MILESTONE / LEAD OPTIMISATION

Build on the selected peptide leads.

The planned next step is lead optimisation, followed by further evaluation of the refined leads.

Discuss this programme

“Completed” refers to the discovery stages shown. Lead optimisation is planned; future preclinical and clinical stages are prospective and depend on results and development decisions. Research candidates are not approved medicines.

Advance the next
stage with us.

We welcome research and development partnerships to help advance our selected compounds and peptide leads.

Explore a partnership